What Can IBD Specialists Learn from IL-23 Trials in Dermatology?
IBD
anti-IL-23
psoriasis
Journal
Journal of Crohn's & colitis
ISSN: 1876-4479
Titre abrégé: J Crohns Colitis
Pays: England
ID NLM: 101318676
Informations de publication
Date de publication:
11 May 2022
11 May 2022
Historique:
entrez:
13
5
2022
pubmed:
14
5
2022
medline:
18
5
2022
Statut:
ppublish
Résumé
The advent of biologic drugs revolutionised the treatment of many chronic inflammatory diseases in rheumatology, dermatology, and gastroenterology. The introduction of different targeted agents closely followed the increase in knowledge of pathogenic mechanisms. The identification of IL-23 as a master regulator of 'pathogenic' inflammation and the consequent efficacy of IL-23 blocking agents were first proofed in psoriasis and then in other inflammatory diseases such as psoriatic arthritis and Crohn's disease. We reviewed all available results from anti-Il-23 clinical trials for psoriasis, focusing on data of IBDologists' interest. Regarding guselkumab, we analysed data from phase III clinical trials VOYAGE1, VOYAGE2, and NAVIGATE. For risankizumab, we reported efficacy and safety results from UltIMMa-1, UltIMMa-2, and IMMvent clinical trials, and tildrakizumab was evaluated by analysing data from reSURFACE1 and reSURFACE2 studies. Data from all the clinical trials that we reported showed both the efficacy of all three anti-IL-23 drugs in psoriasis and the safety of this class; in particular, no gastrointestinal side effects were observed in those studies. IL-23 blockers have shown promising short- and long-term results in psoriasis, with a major safety profile and no negative interactions with gastrointestinal system. Anti-IL-23 indication for psoriatic arthritis is very recent and for IBD is still to come. Therefore, dermatologists are accumulating long-term experience with these drugs, both in clinical trials and in real-world evidence, which can help gastroenterologists in the management of IBD patients.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
The advent of biologic drugs revolutionised the treatment of many chronic inflammatory diseases in rheumatology, dermatology, and gastroenterology. The introduction of different targeted agents closely followed the increase in knowledge of pathogenic mechanisms. The identification of IL-23 as a master regulator of 'pathogenic' inflammation and the consequent efficacy of IL-23 blocking agents were first proofed in psoriasis and then in other inflammatory diseases such as psoriatic arthritis and Crohn's disease.
METHODS
METHODS
We reviewed all available results from anti-Il-23 clinical trials for psoriasis, focusing on data of IBDologists' interest. Regarding guselkumab, we analysed data from phase III clinical trials VOYAGE1, VOYAGE2, and NAVIGATE. For risankizumab, we reported efficacy and safety results from UltIMMa-1, UltIMMa-2, and IMMvent clinical trials, and tildrakizumab was evaluated by analysing data from reSURFACE1 and reSURFACE2 studies.
RESULTS
RESULTS
Data from all the clinical trials that we reported showed both the efficacy of all three anti-IL-23 drugs in psoriasis and the safety of this class; in particular, no gastrointestinal side effects were observed in those studies. IL-23 blockers have shown promising short- and long-term results in psoriasis, with a major safety profile and no negative interactions with gastrointestinal system.
CONCLUSIONS
CONCLUSIONS
Anti-IL-23 indication for psoriatic arthritis is very recent and for IBD is still to come. Therefore, dermatologists are accumulating long-term experience with these drugs, both in clinical trials and in real-world evidence, which can help gastroenterologists in the management of IBD patients.
Identifiants
pubmed: 35553663
pii: 6584455
doi: 10.1093/ecco-jcc/jjac023
pmc: PMC9097670
doi:
Substances chimiques
Interleukin-23
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
ii20-ii29Subventions
Organisme : AbbVie
Organisme : Fondazione Cariplo
ID : 1833073
Organisme : Italian Ministry of Health
ID : CO-2018-12365521
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation.
Références
J Immunol. 2015 Aug 1;195(3):780-8
pubmed: 26188072
Curr Probl Dermatol. 2018;53:49-63
pubmed: 29131037
Lancet. 2019 Sep 7;394(10201):831-839
pubmed: 31402114
Ital J Dermatol Venerol. 2022 Apr;157(2):200-201
pubmed: 33982554
N Engl J Med. 2016 Jul 28;375(4):345-56
pubmed: 27299809
J Allergy Clin Immunol. 2014 Apr;133(4):1032-40
pubmed: 24679469
Psoriasis (Auckl). 2018 Nov 13;8:83-92
pubmed: 30519540
Ann Rheum Dis. 2020 Sep;79(9):1132-1138
pubmed: 32719044
J Am Acad Dermatol. 2017 Mar;76(3):418-431
pubmed: 28057361
J Immunol. 2014 Apr 1;192(7):3111-20
pubmed: 24610014
Gastroenterology. 2008 Oct;135(4):1130-41
pubmed: 18706417
Br J Dermatol. 1999 Aug;141(2):185-91
pubmed: 10468786
N Engl J Med. 2010 Apr 15;362(15):1383-95
pubmed: 20393175
J Allergy Clin Immunol. 2015 Jul;136(1):116-124.e7
pubmed: 25769911
J Dermatolog Treat. 2022 May;33(3):1638-1642
pubmed: 33555951
Front Pharmacol. 2021 Nov 04;12:774808
pubmed: 34803716
Br J Dermatol. 2018 Sep;179(3):615-622
pubmed: 29742274
Acta Derm Venereol. 2021 Nov 30;101(11):adv00605
pubmed: 34596230
N Engl J Med. 2017 Apr 20;376(16):1551-1560
pubmed: 28423301
J Am Acad Dermatol. 2008 Jan;58(1):106-15
pubmed: 17936411
J Crohns Colitis. 2016 Nov;10(11):1259-1266
pubmed: 27566367
J Clin Med. 2021 Aug 26;10(17):
pubmed: 34501272
Nat Commun. 2014 Dec 03;5:5621
pubmed: 25470744
J Gastroenterol. 2018 May;53(5):585-590
pubmed: 29556726
J Am Acad Dermatol. 2017 Mar;76(3):405-417
pubmed: 28057360
Am J Clin Dermatol. 2018 Dec;19(6):907-918
pubmed: 30467781
BMJ Open. 2014 Apr 29;4(4):e005091
pubmed: 24785401
Dermatol Ther. 2022 Feb;35(2):e15228
pubmed: 34820969
Acta Derm Venereol. 2020 Jan 30;100(3):adv00032
pubmed: 31971601
Br J Dermatol. 2020 Mar;182(3):605-617
pubmed: 31218661
Br J Dermatol. 2020 Aug;183(2):373-374
pubmed: 32343839
Lancet. 2018 Aug 25;392(10148):650-661
pubmed: 30097359
Int J Mol Sci. 2010 Feb 26;11(3):789-806
pubmed: 20479986
Br J Dermatol. 2018 Jan;178(1):114-123
pubmed: 28635018
Int J Dermatol. 2020 Aug;59(8):e267-e268
pubmed: 32557532
Br J Dermatol. 2020 Jan;182(1):180-189
pubmed: 30916381
Biomedicines. 2021 Oct 21;9(11):
pubmed: 34829740
Br J Dermatol. 2015 Oct;173(4):930-9
pubmed: 26042589
N Engl J Med. 2019 Sep 26;381(13):1201-1214
pubmed: 31553833
Lancet. 2017 Jul 15;390(10091):276-288
pubmed: 28596043
Lancet. 2001 Jun 9;357(9271):1842-7
pubmed: 11410193
Am J Clin Dermatol. 2019 Apr;20(2):295-306
pubmed: 30924030
Exp Dermatol. 2020 Jul;29(7):630-638
pubmed: 32476200
J Invest Dermatol. 2021 Jul;141(7):1707-1718.e9
pubmed: 33524368
Cutis. 2020 Feb;105(2):89-91;E2;E3
pubmed: 32186523
Br J Dermatol. 2020 Apr;182(4):840-848
pubmed: 31225638
J Dermatolog Treat. 2022 May;33(3):1703-1706
pubmed: 33691568
Lancet. 2019 Aug 17;394(10198):576-586
pubmed: 31280967